The estimated Net Worth of Murray Brennan is at least $552 Tausend dollars as of 20 November 2017. Murray Brennan owns over 20,000 units of Alaunos Therapeutics Inc stock worth over $65,088 and over the last 18 years Murray sold ZIOP stock worth over $486,550.
Murray has made over 7 trades of the Alaunos Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Murray exercised 20,000 units of ZIOP stock worth $54,600 on 20 November 2017.
The largest trade Murray's ever made was selling 40,000 units of Alaunos Therapeutics Inc stock on 3 June 2015 worth over $388,000. On average, Murray trades about 5,400 units every 95 days since 2006. As of 20 November 2017 Murray still owns at least 74,814 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Murray Brennan stock trades at the bottom of the page.
Murray's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON, MA, 02129.
Over the last 18 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk und Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include: